A proteomics analysis of serum samples obtained from patients with T1D at the baseline and 1 year after verapamil or placebo treatment. Verapamil treatment has a beneficial effect on β-cells via the downregulation of both TXNIP and IGFBP3 and the increase in IGF-1 signaling. Here, IGF1 is linked to type 1 diabetes mellitus.